Current Diabetes Reports

, Volume 7, Issue 1, pp 1–2

Leptin and adiponectin: Their role in diabetes

Invited Commentary


  1. 1.
    Zhang Y, Proenca R, Maffei M, et al.: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425–432.PubMedCrossRefGoogle Scholar
  2. 2.
    Farooqi IS, Jebb SA, Langmack G, et al.: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341:879–884.PubMedCrossRefGoogle Scholar
  3. 3.
    Farooqi IS, Matarese G, Lord GM, et al.: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093–1103.PubMedCrossRefGoogle Scholar
  4. 4.
    Chan JL, Mantzoros CS: Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005, 366:74–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Harris RB, Zhou J, Redmann SM Jr, et al.: A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998, 139:8–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Javor ED, Cochran EK, Musso C, et al.: Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005, 54:1994–2002.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee JH, Chan JL, Sourlas E, et al.: Recombinant methionyl human therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy (HAART). J Clin Endocrinol Metab 2006, 91:2605–2611.PubMedCrossRefGoogle Scholar
  8. 8.
    Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005–2010.PubMedCrossRefGoogle Scholar
  9. 9.
    Berg AH, Combs TP, Du X, et al.: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947–953.PubMedCrossRefGoogle Scholar
  10. 10.
    Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731–737.PubMedCrossRefGoogle Scholar
  11. 11.
    Fain JN, Madan AK, Hiler ML, et al.: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273–2282.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang WS, Lee WJ, Funahashi T, et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86:3815–3819.PubMedCrossRefGoogle Scholar
  13. 13.
    Kelesidis I, Kelesidis T, Mantzoros CS: Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221–1225.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288–1295.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations